Q2 2026 Maravai LifeSciences Holdings Inc Earnings Call Transcript
Key Points
- Maravai LifeSciences Holdings Inc (MRVI) delivered strong Q2 2026 results with revenue of $51.4 million, a 9% year-over-year increase, and adjusted EBITDA improved by $19.1 million to $8.7 million.
- TriLink revenue grew 12% year-over-year, driven by a 55% surge in GMP consumables and a 17% increase in discovery mRNA, reflecting robust demand and successful commercial execution.
- The company significantly strengthened its balance sheet by refinancing debt, reducing borrowings to approximately $150 million, cutting debt in half since the start of 2026, and extending maturities to 2032.
- Innovation momentum is strong, with ModTail adoption exceeding 125 customers within a year of launch, and the upcoming GMP-grade ModTail launch is expected to drive future growth.
- Cygnus delivered its fifth consecutive quarter of growth, with revenue up 3% year-over-year and adjusted EBITDA margins of 68%, showcasing stable, high-margin recurring revenue.
- The company raised its full-year 2026 adjusted EBITDA guidance to $33-$35 million, reflecting improved profitability and confidence in the business outlook.
- Maravai LifeSciences Holdings Inc (MRVI) reported a GAAP net loss of $21.6 million in Q2 2026, though this was an improvement from the $69.8 million loss in the prior year period.
- The company maintained its revenue guidance of $205-$215 million, citing potential timing variability in large GMP consumables and CDMO orders, which could lead to quarterly fluctuations.
- CDMO revenue declined year-over-year in Q2, in line with expectations but highlighting the project-based and inherently variable nature of this business segment.
- GMP ModTail is not expected to contribute to revenue until 2027, as the company plans to launch the GMP-grade product later this year but anticipates orders only next year.
- The company faces uncertainty in the timing of large orders, with some deals potentially slipping into 2027, which could impact near-term revenue visibility.
- Cygnus growth remains modest at 3% year-over-year, and the company noted that mass spec analytical services have a longer sales cycle, potentially limiting near-term contribution.
Hello and welcome everyone joining today's Maravai LifeSciences Q2 2026 results earnings call. (Operator Instructions) Please note this call is being recorded, and we are standing by should you need any assistance.
It is now my pleasure to turn the meeting over to Deb Hart. Please go ahead.
Good afternoon, everyone. Thanks for joining us for our second-quarter 2026 earnings call.
The press release and slides accompanying today's call are available at investors.maravai.com.
As you can see from the agenda on slide 2, our CEO, Bernd Brust, will provide a business update; and our CFO, Raj Asarpota, will review our financial results.
Dr. Chanfeng Zhao, our Chief Scientific Officer; and Kurt Oreshack, our Executive Vice President and General Counsel, will join us for the Q&A session.
Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. Actual results could differ materially from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
